Fig. 2.
Treatment approaches in synchronous (dark bars) and metachronous (light bars) oligo-metastatic PCa. ADT, androgen deprivation therapy; MDT, metastasis-directed therapy; NHT, new hormonal therapy.
Treatment approaches in synchronous (dark bars) and metachronous (light bars) oligo-metastatic PCa. ADT, androgen deprivation therapy; MDT, metastasis-directed therapy; NHT, new hormonal therapy.
